![Avania
Appoints
Recognized
Clinical
Research
and
Medtech
Industry
Leader
Jason
Monteleone
as
President
and
CEO](https://euro.dayfr.com/temp/resized/medium_2024-09-04-15490e64bf.jpg)
BILTHOVEN, Netherlands and BOSTON, USA, September 04, 2024–(BUSINESS WIRE)–Avania, a global leader in the medtech clinical research industry providing product development, market access and contract research services, today announced the appointment of Jason Monteleone as President and CEO, effective September 2, 2024. Jason Monteleone succeeds Sapna Hornyak, who has served as President and CEO since 2019. Under Sapna Hornyak’s leadership, Avania has built a robust, integrated global medical technology platform. Jason will continue to drive growth, increased therapeutic focus and innovation initiatives to strengthen Avania’s position as a leading medtech clinical research organization.
With over 25 years of experience in the clinical research, medical device and life sciences industries, Jason Monteleone brings extensive expertise in growth, innovation and operational excellence. From 2017 to 2021, Jason Monteleone served as CEO of Clinipace, a mid-sized global clinical research organization, during which time the company grew revenue by 65% prior to its acquisition by dMed in April 2021. While serving as CFO of Theorem Clinical Research, a mid-sized global clinical research organization focused on pharmaceutical and medical device studies, the company doubled in revenue and headcount prior to its acquisition by Chiltern International in September 2015. Most recently, Jason Monteleone served as President of Ancillare, a global provider of clinical trial accessories and equipment.
Jason Monteleone also serves as a member of the Board of Directors and Chairman of the Audit Committee of the Drug Information Association (DIA), the leading international multidisciplinary life sciences association dedicated to fostering collaboration in the development of drugs, devices and diagnostics for a healthier world. Jason Monteleone is the founder of Pivotal Financial Consulting, an acquisition, growth strategy and innovation advisory firm for investors and companies in the clinical research industry. He also served as CFO of VIASYS Healthcare, a publicly traded medical device company, prior to its acquisition by Cardinal Health and merger to become CareFusion.
“I am honored to join Avania and lead this exceptional team during this exciting time for our industry,” said Monteleone. “Avania partners with some of the world’s most innovative companies in a variety of fields including cardiovascular, neurological, orthopedic and aesthetics. It’s a privilege to partner with our customers as they develop life-changing products, and that’s why we’re passionate about what we do. It’s what drives us to innovate, collaborate and strive for excellence in every project.”
Todd Pope, Avania’s Chairman of the Board, added, “I look forward to working with Jason as Avania continues its mission to make a positive impact for our customers, employees and the entire medtech community. The management team and Board are excited about the future of Avania at the forefront of innovation and operational excellence.”
Edouard Pillot, Partner and Co-Director of Astorg Mid-Cap, Avania’s majority shareholder, said, “We are delighted to welcome Jason as Avania’s CEO. His exceptional track record of growth and operational excellence, combined with his experience in scaling businesses, make him the ideal leader to lead Avania towards its next development objective. With his extensive expertise in the clinical research and medtech sectors, Jason will drive innovation and deliver unique solutions to our customers. We look forward to the long-term value that Avania will create for its stakeholders under his leadership.”
About Avania
Avania is one of the world’s leading contract research organizations. The Company offers a full range of services focused on clinical study management for medical devices, IVDs, biologics and device-drug combination products, on a global scale. With the same personalized approach, Avania supports products from the initial phase where the drug is administered to humans through the post-marketing phase. If you need help advancing your medical technology, Avania is the place to go. Avania’s mission is to be your trusted global partner throughout your medical technology journey, from innovation to commercialization, to improve the health and well-being of patients.
The text of the press release resulting from a translation should in no way be considered official. The only version of the press release that is authoritative is that of the press release in its original language. The translation must always be compared with the source text, which will constitute precedent.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904187719/fr/
Contacts
Holli Kroeker
+1 308-338-2358
[email protected]
Jasmine Saba
+1 214 418 3201
[email protected]